

Structure of the mammalian TSPO/PBR protein

Mariusz Jaremko^{*1}, Łukasz Jaremko^{*†1}, Garima Jaipuria^{*}, Stefan Becker^{*} and Markus Zweckstetter^{*†‡2}

^{*}Max-Planck-Institut für Biophysikalische Chemie, Göttingen 37077, Germany

[†]Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen 37077, Germany

[‡]Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center, Göttingen 37077, Germany

Abstract

The 3D structure of the 18-kDa transmembrane (TM) protein TSPO (translocator protein)/PBR (peripheral benzodiazepine receptor), which contains a binding site for benzodiazepines, is important to better understand its function and regulation by endogenous and synthetic ligands. We have recently determined the structure of mammalian TSPO/PBR in complex with the diagnostic ligand PK11195 [1-(2-chlorophenyl)-*N*-methyl-*N*-(1-methylpropyl)-3-isoquinolinecarboxamide; Jaremko et al. (2014) *Science* **343**, 1363–1366], providing for the first time atomic-level insight into the conformation of this protein, which is up-regulated in various pathological conditions including Alzheimer's disease and Parkinson's disease. Here, we review the studies which have probed the structural properties of mammalian TSPO/PBR as well as the homologues bacterial tryptophan-rich sensory proteins (TspOs) over the years and provide detailed insight into the 3D structure of mouse TSPO (mTSPO)/PBR in complex with PK11195.

The TSPO/PBR protein

The 18-kDa translocator protein (TSPO)/peripheral benzodiazepine receptor (PBR) is an evolutionarily conserved membrane protein found in most species including bacteria, plants and humans with some exceptions including *Escherichia coli* and *Saccharomyces cerevisiae* [1]. Although expressed throughout the body, human TSPO/PBR is present in high amounts in the outer mitochondrial membrane of steroid-synthesizing cells of the central and the peripheral nervous system [2]. TSPO/PBR was discovered in 1977, when Braestrup et al. [3] observed the existence of specific receptors on the membranes of rat brain cells, which specifically bind to an important group of psychoactive drugs, the benzodiazepines. TSPO/PBR was purified in complex with the voltage-dependent anion channel and the adenine nucleotide transporter from the mitochondrial membrane [4]. TSPO/PBR was referred to as PBR until 2006, when it was renamed due to its potential role in translocation of cholesterol from the outer to the inner mitochondrial membrane [5]. Recent studies, however, challenge the direct involvement of TSPO/PBR in cholesterol transport and steroidogenesis [6–8]. At the same time, TSPO/PBR has been implicated in several biological functions [9], including mitochondrial respiration [10], cell proliferation

[11], immunomodulation and apoptosis [12,13]. In bacteria, tryptophan-rich sensory proteins (TspOs) are associated with the porphyrin biosynthesis pathway and consumption of reactive oxygen species [14].

TSPO/PBR is also important from a medical perspective as its expression is up-regulated in various pathological conditions including Alzheimer's disease, Parkinson's disease and multiple sclerosis [15]. In addition, the TSPO/PBR variant Ala¹⁴⁷Thr is associated with human adult separation anxiety [16]. Increased expression levels of TSPO/PBR can be monitored by positron emission tomography/single photon emission computed tomography. These studies use TSPO/PBR-specific radiolabelled neuroimaging ligands such as [¹¹C](*R*)-PK11195 [1-(2-chlorophenyl)-*N*-methyl-*N*-(1-methylpropyl)-3-isoquinolinecarboxamide] to allow sensitive recognition of lesions and active disease processes in the brain [1,17–19]. TSPO/PBR ligands also have potential therapeutic applications such as attenuation of cancer cell proliferation [20] and neuro-protective effects [21]. Thus, many studies are pursued to develop synthetic ligands that specifically bind to TSPO/PBR and aid in the determination and restoration of active disease areas [15].

Structural properties of TSPO/PBR

A wide range of techniques have been used to probe the structural properties of TSPO/PBR including bioinformatics analysis, MD simulations, CD, IF spectroscopy, EM, NMR spectroscopy and biochemical assays. Analysis of the amino acid sequence of TSPO/PBR points to a high degree of homology between different species (Figure 1A) [22,23]. Hydropathy analysis of TSPO/PBR indicates five stretches of hydrophobic residues (Figure 1B), each long enough to

Key words: dynamics, nuclear magnetic resonance (NMR), peripheral benzodiazepine receptor, 1-(2-chlorophenyl)-*N*-methyl-*N*-(1-methylpropyl)-3-isoquinolinecarboxamide (PK11195), structure, TSPO.


Abbreviations: CRAC, cholesterol recognition amino acid sequence; DPC, dodecylphosphocholine; PBR, peripheral benzodiazepine receptor; PK11195, 1-(2-chlorophenyl)-*N*-methyl-*N*-(1-methylpropyl)-3-isoquinolinecarboxamide; mTSPO, mouse TSPO; R5TspO, TspO from *Rhodobacter sphaeroides*; TM, transmembrane; TSPO, translocator protein; TspO, tryptophan-rich sensory protein.

¹These authors contributed equally to the present work.

² To whom correspondence should be addressed (email Markus.Zweckstetter@dzne.de).

Figure 1 | Sequence properties of mammalian TSPO/PBR

(A) Alignment of the primary sequences of human and mTSPO/PBR. (B) Hydrophobicity of mTSPO/PBR as a function of residue number.



span the bilayer membrane. Early MD simulations predicted an energetically stable arrangement of the five transmembrane (TM) helices of TSPO/PBR with a short intramitochondrial N-terminus and a longer C-terminal tail pointing towards the extra-mitochondrial side [24]. These predictions were confirmed by immunodetection of epitope insertions made in the loop regions of TSPO/PBR and also by visualization of cysteine residues using thiol-labelling techniques [25]. Site-directed mutagenesis of specific residues on the C-terminal end led to the identification of a conserved cholesterol recognition amino acid sequence (CRAC) [26]. The far UV CD spectrum of mouse TSPO/PBR (mTSPO/PBR) solubilized in dodecylphosphocholine (DPC) micelles indicates a helical content of 45 %, which is further increased upon binding of PK11195 [27]. Changes in the secondary structure content upon ligand addition have also been confirmed by studying the hydrogen/deuterium exchange kinetics of amide protons by mid-IF spectroscopy. Increase in exchange rates and percentage of non-exchangeable amide protons upon binding of PK11195 to TSPO/PBR suggests that a more compact TSPO/PBR structure is generated on ligand addition [28].

The tendency of TSPO/PBR to form oligomeric complexes has been supported by biochemical experiments, as well as EM. While Lacapere and co-workers [29] observed association of at least four monomer units of mTSPO/PBR, Korkhov et al. [30] determined a low-resolution dimeric architecture of the homologues TspO from *Rhodobacter sphaeroides* (RsTspO) based on cryoEM of helical crystals. Consistent with the pronounced tendency of RsTspO to dimerize, two pentahelical RsTspO units were arranged as a dimer in the lipid bilayer [30]. Because TM helix 1 is the least conserved of the five TM regions and is more polar in RsTspO than in mTSPO/PBR, where the functional unit is

a monomer, we suggested that TM helix 1 is involved in the dimer interface of RsTspO [22]. However, alternative models were also proposed [31,32].

NMR spectroscopy of membrane proteins


NMR spectroscopy and X-ray crystallography are two powerful techniques capable of determining the 3D structure of protein molecules at atomic resolution. While structure determination by X-ray crystallography requires the freezing of proteins at cryogenic temperatures in a crystal lattice, NMR spectroscopy is capable of determining the structure of both soluble and membrane proteins at near physiological temperatures. In addition, NMR spectroscopy can provide insight into time-dependent chemical phenomena, including reaction kinetics and dynamics in solution and the solid state at atomic resolution [33]. Although the cumulative molecular mass of a protein–detergent complex, the oligomerization state of the protein and a limited dispersion of an NMR spectrum may pose formidable hurdles for the structural study of membrane proteins by solution-state NMR, significant advances in sample preparation and experimental NMR methods have established NMR spectroscopy as a powerful method for studying membrane proteins both in the solution and in the solid state [34,35].

3D structure of mammalian TSPO/PBR in complex with PK11195

We recently determined the 3D structure of the 169-residue mTSPO/PBR in complex with (*R*)-PK11195 [36]. The structure was solved using solution NMR spectroscopy with mTSPO/PBR solubilized in DPC micelles. Consistent

Figure 2 | 3D structure of mTSP0/PBR in complex with (R)-PK11195

The backbone of mTSP0/PBR (PDB code: 2MGY; [36]) is shown in ribbon representation. The approximate positioning in the membrane is indicated in blue. The membrane thickness was estimated using the OPM server (<http://opm.phar.umich.edu/server.php>). Flexible C- and N-termini are marked by red and blue dots respectively. (R)-PK11195 is depicted in sticks. The side chains of four conserved tryptophan residues, out of a total of 12 tryptophan residues in mTSP0/PBR, are shown.



with the ability of mammalian TSP0/PBR to bind synthetic ligands and function as monomeric unit [37], mTSP0/PBR solubilized in DPC micelles is monomeric [36]. The mTSP0/PBR–PK11195 complex structure is characterized by a tight packing of its α -helical TM regions (Figure 2). When viewed from the extra-mitochondrial side, the clockwise order of the five TM helices is TM1–TM2–TM5–TM4–TM3. The same TM topology was recently observed for two bacterial tryptophan-rich sensory proteins [32,38]. mTSP0/PBR has a high content of proline residues in its TM region. TM1 is perturbed by Pro¹⁵, whereas TM2 and TM3 contain the double-proline motifs Pro⁴⁴–Pro⁴⁵ and Pro⁹⁶–Pro⁹⁷ respectively. Proline residues are also present at positions 51 in TM2 and 81 in TM3. TM5 has a proline at position 139, which kinks this helix toward the intra-mitochondrial side. The most stable TM segments of the mTSP0/PBR structure are TM4 and TM5 according to hydrogen/deuterium exchange experiments [36]. TM4 and TM5 are the evolutionary most conserved regions of TSP0/PBR.

Mammalian TSP0/PBR is homologous to bacterial TspO proteins, which have a high content of tryptophan residues [39]. Accordingly, several tryptophan residues of mTSP0/PBR are conserved such as Trp³³, which is located in the short α' -helix in the TM1–TM2 loop, Trp⁵³ in TM2, Trp¹²⁶


at the end of TM4 and Trp¹⁴³ in TM5 (Figure 2). Both Trp⁵³ and Trp¹⁴³ are in close contact to each other and contribute to the TM2/TM5 interface. Trp⁵³ and Trp¹⁴³ point toward the interior of the protein and make numerous contacts to neighbouring residues, consistent with the conservation of TM2, TM4 and TM5.

Topological analysis has suggested that the flexible C-terminus, the TM3–TM4 loop and the TM1–TM2 loop are located on the extra-mitochondrial side [25]. The intra-mitochondrial parts of TSP0/PBR are then formed by the N-terminus, the TM4–TM5 loop and the TM2–TM3 loop (Figure 2). Loop regions in mTSP0/PBR are short with the exception of the TM1–TM2 loop, which contains a seven-residue-long α -helical motif (Figure 2). Loops are mostly well-defined in the structure and have dynamic properties comparable to the TM α -helices [36]. The long TM1–TM2 loop forms a lid closing the top of the TM bundle and protects the PK11195 ligand from leaving the protein (Figure 2). On the intra-mitochondrial side, the TM2–TM3 loop is protruding from the membrane together with α -helical extensions of the C-terminal end of TM2 and the N-terminal end of TM3.

The C- and N-terminus of mTSP0/PBR in complex with PK11195 have no stable structure as evidenced by their close to random coil chemical shifts as well as

Figure 3 | The binding site for PK11195 and porphyrin

Selected view of the binding pocket of PK11195 as seen in the structure of mTSPO/PBR in complex with PK11195 (PDB code: 2MGY). Colour coding of helices is the same as in Figure 2. Residues, which are in direct contact with (R)-PK11195, are marked. Residues, which were additionally found to be important for ligand binding in mutagenesis studies [42,44,45], are labelled with italic characters. The orange ellipsoid highlights the region, which is important for binding to PK11195 and porphyrins. The polymorphic residue Ala¹⁴⁷ is shown in bold.



negative steady-state Nuclear Overhauser Enhancement values [36]. The C-terminus is highly positively charged, whereas the regions exposed to the intra-mitochondrial side have an equal number of positive and negative charges [36]. The distribution of positively and negatively charged patches on the extra- and intra-mitochondrial side might be important for recognition of endogenous ligands and proteins interacting with TSPO/PBR, such as steroid acute regulatory protein and diazepam-binding inhibitor [40].

Interaction with small molecules

PK11195 binds with nanomolar affinity to TSPO/PBR from different eukaryotic species [41]. Residues, which are important for binding to PK11195, were identified by site-directed mutagenesis [42] and their importance is supported by the 3D structure of the mTSPO/PBR–PK11195 complex. In particular, residues Ala²³, Val²⁶, Leu⁴⁹, Ala⁵⁰, Ile⁵², Trp¹⁰⁷, Ala¹¹⁰, Leu¹¹⁴, Ala¹⁴⁷, Leu¹⁵⁰ of mTSPO/PBR directly contact (R)-PK11195 (Figure 3) [36]. On the other hand, PK11195 binds with an at least 1000-fold lower affinity to *Rs*TspO [43], suggesting possible structural differences between mammalian TSPO/PBR and bacterial TspO proteins (consistent with recent structural studies of two bacterial tryptophan-rich sensory proteins [32,38]). In case of mTSPO/PBR, Glu²⁹ to Ala³⁵ form a short α -helix in the extra-mitochondrial space, whereas the ²⁷RGE²⁹ fragment is missing in the *Rs*TspO sequence. This might lead to a less stable lid on top of the PK11195-binding pocket and contribute to the lower PK11195 affinity of *Rs*TspO. Together with site-directed mutagenesis, the sequence differences support the importance of the TM1–TM2 loop for ligand binding [26,42]. Another region

contributing to the functional and structural differences of mammalian TSPO/PBR and bacterial TspO proteins is probably the TM1 helix, as this is the least conserved region across different species. Indeed, two of the mTSPO/PBR residues, Ala²³ and Val²⁶, which directly contact PK11195, are located in TM1 [36]. The binding cavity identified in the 3D structure of the mTSPO/PBR–PK11195 complex, is likely to be important for several other ligands. In line with this hypothesis, mutagenesis studies and computational analysis have suggested that residues Arg²⁴, Glu²⁹, Leu³¹, Leu³⁷, Lys³⁹, Pro⁴⁰, Ser⁴¹, Trp⁴², Trp¹⁰⁷ and Trp¹⁶¹ of TSPO/PBR (sequence numbering according to the human protein) are important for binding of the ligand Ro5-4864 [42,44,45]. Notably, although PK11195 binds with similar affinity to mutant TSPO/PBR, which carries either an alanine or a threonine at position 147, the rs6971 polymorphism strongly affects the binding of many second generation radioligands to TSPO/PBR [46,47]. This highlights the need to determine the 3D structure of both wild-type and the Ala¹⁴⁷ variant of mammalian TSPO/PBR in complex with different small molecules.

Interaction with endogenous ligands

Numerous endogenous ligands are recognized and bound to TSPO/PBR including porphyrins, products of their degradation and cholesterol [15]. Cholesterol binds with nanomolar affinity to the CRAC motif (residues 147–159) close to the C-terminus of TSPO/PBR [26]. The CRAC motif L/V–X (1–5)–Y–X (1–5)–R/K has also been found in other TM proteins that interact with cholesterol [48]. An NMR analysis of a C-terminal TSPO/PBR peptide (residues 144–169) indicated a helical conformation for the Leu¹⁴⁴ to Ser¹⁵⁹ fragment of the peptide and a groove that could possibly

accommodate a cholesterol molecule [49]. Structural studies on full-length mTSPO/PBR revealed that in complex with PK11195 the CRAC motif forms a well-ordered α -helix [36]. The residues, which mutational analysis has shown to be important for cholesterol binding [26,50], point away from the protein interior towards the hydrophobic environment of the membrane. Together with neighbouring residues in TM4, the CRAC motif is the most stable part of the mTSPO/PBR-PK11195 structure [36].

Porphyrins bind to a different region of TSPO/PBR than cholesterol, such that substitution of Ala¹⁴⁷ by threonine affects binding of porphyrins and second-generation radioligands [14,46,47]. In addition, PK11195 binding to TspO inhibits porphyrin degradation, suggesting that the two molecules compete for the same site (Figure 3), with PK11195 having higher affinity [14].

Concluding remarks

The 3D structure of mTSPO/PBR in complex with PK11195 has provided an important step towards a more detailed understanding of the molecular mechanism of mammalian TSPO/PBR and its interaction with small molecules [36]. Future structural studies will be required to provide insight into the influence of the A¹⁴⁷T polymorphism on the recognition of second-generation radioligands, the analysis of interspecies differences, the structure and dynamics of TSPO/PBR in the absence of high-affinity ligands, the characterization of TSPO/PBR in complex with cholesterol and the binding of TSPO/PBR to other endogenous interaction partners.

Funding

This work was supported by the DFG Collaborative Research Center [grant number 803 project A11 (to M.Z.)]; and the European Research Council [grant number 282008 (to M.Z.)].

References

- Liu, G.J., Middleton, R.J., Hatty, C.R., Kam, W.W., Chan, R., Pham, T., Harrison-Brown, M., Dodson, E., Veale, K. and Banati, R.B. (2014) The 18 kDa translocator protein, microglia and neuroinflammation. *Brain Pathol.* **24**, 631–653 [CrossRef PubMed](#)
- Antkiewicz-Michaluk, L., Guidotti, A. and Krueger, K.E. (1988) Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands. *Mol. Pharmacol.* **34**, 272–278 [PubMed](#)
- Braestrup, C., Albrechtsen, R. and Squires, R.F. (1977) High densities of benzodiazepine receptors in human cortical areas. *Nature* **269**, 702–704 [CrossRef PubMed](#)
- McEnery, M.W., Snowman, A.M., Trifiletti, R.R. and Snyder, S.H. (1992) Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. *Proc. Natl. Acad. Sci. U.S.A.* **89**, 3170–3174 [CrossRef PubMed](#)
- Papadopoulos, V., Baraldi, M., Guilarte, T.R., Knudsen, T.B., Lacapere, J.J., Lindemann, P., Norenberg, M.D., Nutt, D., Weizman, A., Zhang, M.R. and Gavish, M. (2006) Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. *Trends Pharmacol. Sci.* **27**, 402–409 [CrossRef PubMed](#)
- Banati, R.B., Middleton, R.J., Chan, R., Hatty, C.R., Wai-Ying Kam, W., Quin, C., Graeber, M.B., Parmar, A., Zahra, D., Callaghan, P. et al. (2014) Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. *Nat. Commun.* **5**, 5452 [CrossRef PubMed](#)
- Stocco, D.M. (2014) The role of PBR/TSPO in steroid biosynthesis challenged. *Endocrinology* **155**, 6–9 [CrossRef PubMed](#)
- Tu, L.N., Morohaku, K., Manna, P.R., Pelton, S.H., Butler, W.R., Stocco, D.M. and Selvaraj, V. (2014) Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no effects on steroid hormone biosynthesis. *J. Biol. Chem.* **289**, 27444–27454 [CrossRef PubMed](#)
- Gatliff, J. and Campanella, M. (2012) The 18 kDa translocator protein (TSPO): a new perspective in mitochondrial biology. *Curr. Mol. Med.* **12**, 356–368 [PubMed](#)
- Hirsch, J.D., Beyer, C.F., Malkowitz, L., Beer, B. and Blume, A.J. (1989) Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control. *Mol. Pharmacol.* **35**, 157–163 [PubMed](#)
- Ikezaki, K. and Black, K.L. (1990) Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine. *Cancer Lett.* **49**, 115–120 [CrossRef PubMed](#)
- Lin, R., Angelin, A., Da Settimo, F., Martini, C., Taliani, S., Zhu, S. and Wallace, D.C. (2014) Genetic analysis of dTSPO, an outer mitochondrial membrane protein, reveals its functions in apoptosis, longevity, and Ab42-induced neurodegeneration. *Aging Cell* **13**, 507–518 [CrossRef PubMed](#)
- Papadopoulos, V., Dharmarajan, A.M., Li, H., Culty, M., Lemay, M. and Sridaran, R. (1999) Mitochondrial peripheral-type benzodiazepine receptor expression. Correlation with gonadotropin-releasing hormone (GnRH) agonist-induced apoptosis in the corpus luteum. *Biochem. Pharmacol.* **58**, 1389–1393 [CrossRef PubMed](#)
- Ginter, C., Kiburu, I. and Boudker, O. (2013) Chemical catalysis by the translocator protein (18 kDa). *Biochemistry* **52**, 3609–3611 [CrossRef PubMed](#)
- Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T.C., Fan, J., Akula, N., Groyer, G., Adams, D. and Schumacher, M. (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. *Nat. Rev. Drug. Discov.* **9**, 971–988 [CrossRef PubMed](#)
- Papadopoulos, V., Widmaier, E.P., Amri, H., Zilz, A., Li, H., Culty, M., Castello, R., Philip, G.H., Sridaran, R. and Drieu, K. (1998) *In vivo* studies on the role of the peripheral benzodiazepine receptor (PBR) in steroidogenesis. *Endocr. Res.* **24**, 479–487 [CrossRef PubMed](#)
- Gerhard, A. (2013) Imaging of neuroinflammation in parkinsonian syndromes with positron emission tomography. *Curr. Neurol. Neurosci. Rep.* **13**, 405 [CrossRef PubMed](#)
- Trapani, A., Palazzo, C., de Candia, M., Lasorsa, F.M. and Trapani, G. (2013) Targeting of the translocator protein 18 kDa (TSPO): a valuable approach for nuclear and optical imaging of activated microglia. *Bioconjug. Chem.* **24**, 1415–1428 [CrossRef PubMed](#)
- Dolle, F., Luus, C., Reynolds, A. and Kassiou, M. (2009) Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. *Curr. Med. Chem.* **16**, 2899–2923 [CrossRef PubMed](#)
- Santidrian, A.F., Cosialls, A.M., Coll-Mulet, L., Iglesias-Serret, D., de Frias, M., Gonzalez-Girones, D.M., Campas, C., Domingo, A., Pons, G. and Gil, J. (2007) The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells. *Haematologica* **92**, 1631–1638 [CrossRef PubMed](#)
- Rupprecht, R., Rammes, G., Eser, D., Baghai, T.C., Schule, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H.O., Chaperon, F. et al. (2009) Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. *Science* **325**, 490–493 [CrossRef PubMed](#)
- Jaremko, L., Jaremko, M., Becker, S. and Zweckstetter, M. (2014) Toward the functional oligomerization state of tryptophan-rich sensory proteins. *Protein Sci.* **23**, 1154–1160 [CrossRef PubMed](#)
- Yeliseev, A.A., Krueger, K.E. and Kaplan, S. (1997) A mammalian mitochondrial drug receptor functions as a bacterial “oxygen” sensor. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 5101–5106 [CrossRef PubMed](#)
- Bernassau, J.M., Reversat, J.L., Ferrara, P., Caput, D. and Lefur, G. (1993) A 3D model of the peripheral benzodiazepine receptor and its implication in intra mitochondrial cholesterol transport. *J. Mol. Graph.* **11**, 236–244, 235 [CrossRef PubMed](#)
- Joseph-Liauzun, E., Delmas, P., Shire, D. and Ferrara, P. (1998) Topological analysis of the peripheral benzodiazepine receptor in yeast mitochondrial membranes supports a five-transmembrane structure. *J. Biol. Chem.* **273**, 2146–2152 [CrossRef PubMed](#)

- 26 Li, H. and Papadopoulos, V. (1998) Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. *Endocrinology* **139**, 4991–4997 [PubMed](#)
- 27 Murail, S., Robert, J.C., Coic, Y.M., Neumann, J.M., Ostuni, M.A., Yao, Z.X., Papadopoulos, V., Jamin, N. and Lacapere, J.J. (2008) Secondary and tertiary structures of the transmembrane domains of the translocator protein TSPO determined by NMR. Stabilization of the TSPO tertiary fold upon ligand binding. *Biochim. Biophys. Acta* **1778**, 1375–1381 [CrossRef](#) [PubMed](#)
- 28 Lacapere, J.J., Iatmanen-Harbi, S., Senicourt, L., Lequin, O., Tekely, P., Purusottam, R.N., Hellwig, P., Kriegel, S., Ravaud, S., Juillan-Binard, C. et al. (2014) Structural Studies of TSPO, a mitochondrial membrane protein. In *Membrane Proteins Production for Structural Analysis* (Mus-Veteau, I., ed.), pp. 393–421, Springer, New York [CrossRef](#)
- 29 Teboul, D., Beaufils, S., Taveau, J.C., Iatmanen-Harbi, S., Renault, A., Venien-Bryan, C., Vie, V. and Lacapere, J.J. (2012) Mouse TSPO in a lipid environment interacting with a functionalized monolayer. *Biochim. Biophys. Acta* **1818**, 2791–2800 [CrossRef](#) [PubMed](#)
- 30 Korkhov, V.M., Sachse, C., Short, J.M. and Tate, C.G. (2010) Three-dimensional structure of TspO by electron cryomicroscopy of helical crystals. *Structure* **18**, 677–687 [CrossRef](#) [PubMed](#)
- 31 Hinsén, K., Vaitinadapou, A., Ostuni, M.A., Etchebest, C. and Lacapere, J.J. (2015) Construction and validation of an atomic model for bacterial TSPO from electron microscopy density, evolutionary constraints, and biochemical and biophysical data. *Biochim. Biophys. Acta* **1848**, 568–580 [CrossRef](#) [PubMed](#)
- 32 Li, F., Liu, J., Zheng, Y., Garavito, R.M. and Ferguson-Miller, S. (2015) *Science* **347**, 555–558
- 33 Cavanagh, J., Fairbrother, W.J., Palmer, A.G., Rance, M. and Skelton, N.J. (2007) *Protein Nmr Spectroscopy Principles and Practice* Second Edition Preface to the First Edition. *Protein Nmr Spectroscopy: Principles and Practice*, 2nd Edition, Vii-X
- 34 Kim, H.J., Howell, S.C., Van Horn, W.D., Jeon, Y.H. and Sanders, C.R. (2009) Recent advances in the application of solution NMR spectroscopy to multi-span integral membrane proteins. *Prog. Nucl. Magn. Reson. Spectrosc.* **55**, 335–360 [CrossRef](#) [PubMed](#)
- 35 Opella, S.J. (2013) Structure determination of membrane proteins by nuclear magnetic resonance spectroscopy. *Annu. Rev. Anal. Chem.* **6**, 305–328 [CrossRef](#)
- 36 Jaremko, L., Jaremko, M., Giller, K., Becker, S. and Zweckstetter, M. (2014) Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. *Science* **343**, 1363–1366 [CrossRef](#) [PubMed](#)
- 37 Lacapere, J.J., Delavoie, F., Li, H., Peranzi, G., Maccario, J., Papadopoulos, V. and Vidic, B. (2001) Structural and functional study of reconstituted peripheral benzodiazepine receptor. *Biochem. Biophys. Res. Commun.* **284**, 536–541 [CrossRef](#) [PubMed](#)
- 38 Guo, Y., Kalathur, R.C., Liu, Q., Kloss, B., Bruni, R., Ginter, C., Kloppmann, E., Rost, B. and Hendrickson, W.A. (2015) *Science* **347**, 551–555
- 39 Fan, J., Lindemann, P., Feuilloley, M.G. and Papadopoulos, V. (2012) Structural and functional evolution of the translocator protein (18 kDa). *Curr. Mol. Med.* **12**, 369–386 [PubMed](#)
- 40 Rone, M.B., Fan, J. and Papadopoulos, V. (2009) Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. *Biochim. Biophys. Acta* **1791**, 646–658 [CrossRef](#) [PubMed](#)
- 41 Owen, D.R. and Matthews, P.M. (2011) Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. *Int. Rev. Neurobiol.* **101**, 19–39 [CrossRef](#) [PubMed](#)
- 42 Farges, R., Joseph-Liauzun, E., Shire, D., Caput, D., Le Fur, G. and Ferrara, P. (1994) Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5–4864. *Mol. Pharmacol.* **46**, 1160–1167 [PubMed](#)
- 43 Li, F., Xia, Y., Meiler, J. and Ferguson-Miller, S. (2013) Characterization and modeling of the oligomeric state and ligand binding behavior of purified translocator protein 18 kDa from *Rhodobacter sphaeroides*. *Biochemistry* **52**, 5884–5899 [CrossRef](#) [PubMed](#)
- 44 Yeliseev, A.A. and Kaplan, S. (2000) TspO of *Rhodobacter sphaeroides*. A structural and functional model for the mammalian peripheral benzodiazepine receptor. *J. Biol. Chem.* **275**, 5657–5667 [CrossRef](#) [PubMed](#)
- 45 Anzini, M., Cappelli, A., Vomero, S., Seeber, M., Menziani, M.C., Langer, T., Hagen, B., Manzoni, C. and Bourguignon, J.J. (2001) Mapping and fitting the peripheral benzodiazepine receptor binding site by carboxamide derivatives. Comparison of different approaches to quantitative ligand-receptor interaction modeling. *J. Med. Chem.* **44**, 1134–1150 [CrossRef](#) [PubMed](#)
- 46 Owen, D.R., Gunn, R.N., Rabiner, E.A., Bennacef, I., Fujita, M., Kreis, W.C., Innis, R.B., Pike, V.W., Reynolds, R., Matthews, P.M. and Parker, C.A. (2011) Mixed-affinity binding in humans with 18-kDa translocator protein ligands. *J. Nucl. Med.* **52**, 24–32 [CrossRef](#) [PubMed](#)
- 47 Owen, D.R., Yeo, A.J., Gunn, R.N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D.J., Bennacef, I., Parker, C.A. et al. (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. *J. Cereb. Blood Flow Metab.* **32**, 1–5 [CrossRef](#) [PubMed](#)
- 48 Fantini, J. and Barrantes, F.J. (2013) How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains. *Front. Physiol.* **4**, 31 [PubMed](#)
- 49 Jamin, N., Neumann, J.M., Ostuni, M.A., Vu, T.K., Yao, Z.X., Murail, S., Robert, J.C., Giatzakis, C., Papadopoulos, V. and Lacapere, J.J. (2005) Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. *Mol. Endocrinol.* **19**, 588–594 [CrossRef](#) [PubMed](#)
- 50 Li, H., Yao, Z., Degenhardt, B., Teper, G. and Papadopoulos, V. (2001) Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 1267–1272 [CrossRef](#) [PubMed](#)

Received 27 January 2015
doi:10.1042/BST20150029